Q-omics provides the consensus-scored RPEP6 profile across patient tissues and cancer cell-line models. RPEP6 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RPEP6 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, RPEP6 RNA expression shows 10,580 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, KIRC, and TGCT as cancer lineages where RPEP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPEP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPEP6 survival associations across molecular data types. RPEP6 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPEP6 RNA expression–survival associations across cancer types. High RPEP6 expression shows unfavorable associations in UCS, LIHC, UCEC, THCA, MESO and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for RPEP6 RNA expression.
This table summarizes RPEP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPEP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPEP6 shows lower tumor expression in KIRC, THCA and KIRP and higher tumor expression in HNSC. The KIRC box plot shows higher RPEP6 RNA expression in normal versus tumor tissue (log2 FC = −0.116, t-test p < 0.001).
This table shows molecular features associated with RPEP6 in patient tissues and cancer cell lines. In patient samples, RPEP6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
